PCSK9-LYTAC

N/A

Report date: 2026/04/09 13:43:12

Base Information

Drug NamePCSK9-LYTAC

Drug Alias NameN/A

ClassificationBiologics > Lysosome-Targeting Chimaeras (LYTAC)Small molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide aptamer

Mechanisms of ActionProprotein convertase subtilisin kexin type 9 degraders

TargetsProprotein convertase subtilisin kexin type 9

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesUniversity of Chinese Academy of Sciences

China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Chinese Academy of Sciences

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A